{"id":"W2898547742","doi":"10.1093/annonc/mdy289","title":"KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma","year":2018,"lang":"fr","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Dabrafenib; Medicine; Tolerability; Discontinuation; Pembrolizumab; Internal medicine; Placebo; Clinical endpoint; Gastroenterology; Nuclear medicine; Clinical trial; Adverse effect; Metastatic melanoma; Immunotherapy; Cancer; Pathology; Vemurafenib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002400367,0.002598251,0.002175231,0.0005382495,0.0006580622,0.001327406,0.001796686,0.001938265,0.0204631],"category_scores_gemma":[0.001497518,0.001082222,0.001318775,0.0005676616,0.001189934,0.001338296,0.0006777524,0.003797979,0.003820474],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00143237,"about_ca_system_score_gemma":0.002900077,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007120533,"about_ca_topic_score_gemma":0.001919017,"domain_scores_codex":[0.9993134,0.0003420593,0.00003878471,0.0001276835,0.00006595829,0.0001120349],"domain_scores_gemma":[0.9991942,0.0001140919,0.0002207442,0.00007388774,0.00004762269,0.0003494275],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9345756,0.02540189,0.000871435,0.001015298,0.000552648,0.00008713893,0.00008513042,0.0007184905,0.01376621,0.0002605441,0.004803252,0.01786239],"study_design_scores_gemma":[0.9388732,0.05706195,0.001053571,0.00002145036,0.0001771262,0.00006887368,0.00001348405,0.0002943259,0.000874195,0.000111592,0.001436147,0.00001390275],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9253044,0.004171106,0.002594873,0.001793421,0.000650017,0.04244871,0.01396116,0.0006227713,0.008453595],"genre_scores_gemma":[0.9227446,0.002954668,0.005883371,0.003102827,0.0007142435,0.04003896,0.01009641,0.000164645,0.01430031],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0204631,"threshold_uncertainty_score":0.06845593,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0654847845609551,"score_gpt":0.3826286166165271,"score_spread":0.317143832055572,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}